secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001193125-24-056937
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon appoints Santhosh Palani, Ph.D., CFA, to board of directors effective March 4, 2024
--------------------------------------------------------------------------------

- Dr. Palani appointed board member effective March 4, 2024; receives 32,500 share option grant vesting over 3 years.
- He brings experience as former investment partner at PFM Health Sciences and prior roles at NEA, Cowen, Pfizer, Takeda.
- No transactions requiring disclosure under Item 404(a); standard indemnification agreement entered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312524056937/0001193125-24-056937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312524056937/d791106d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-056937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer